NASDAQ · PSNL
Healthcare · Medical - Diagnostics & Research
$14.42
Down-$0.38 (-2.64%)
Updated Aug 15, 2026, 12:06 AM
SID Score
5.9/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
PSNL closed at $14.42 after 20 trading sessions, down 6.30% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 13, 2026 | $14.295 | $14.51 | $14.03 | $14.42 | 1.17M |
| Aug 12, 2026 | $14.03 | $14.28 | $13.87 | $14.21 | 1.55M |
| Aug 11, 2026 | $14.26 | $14.35 | $13.95 | $14.02 | 3.23M |
| Aug 10, 2026 | $14.09 | $14.81 | $14.02 | $14.50 | 4.21M |
| Aug 7, 2026 | $13.24 | $14.30 | $13.13 | $14.16 | 3.21M |
| Aug 6, 2026 | $13.22 | $13.454 | $12.92 | $13.03 | 1.7M |
| Aug 5, 2026 | $13.44 | $13.73 | $13.345 | $13.52 | 1.47M |
| Aug 4, 2026 | $13.40 | $13.60 | $13.08 | $13.52 | 1.68M |
| Aug 3, 2026 | $12.44 | $13.455 | $12.35 | $13.20 | 4.85M |
| Jul 31, 2026 | $12.75 | $12.87 | $12.30 | $12.66 | 2.74M |
| Jul 30, 2026 | $11.89 | $12.32 | $11.82 | $12.28 | 2.74M |
| Jul 29, 2026 | $11.86 | $12.23 | $11.52 | $11.73 | 2.06M |
| Jul 28, 2026 | $11.82 | $12.04 | $11.55 | $11.88 | 2.81M |
| Jul 27, 2026 | $11.95 | $12.14 | $11.57 | $11.98 | 4.62M |
| Jul 24, 2026 | $12.34 | $12.63 | $11.735 | $11.78 | 2.9M |
| Jul 23, 2026 | $12.39 | $12.87 | $12.075 | $12.22 | 3.75M |
| Jul 22, 2026 | $13.34 | $13.41 | $12.435 | $12.47 | 4.04M |
| Jul 21, 2026 | $13.30 | $13.75 | $12.94 | $13.44 | 6.81M |
| Jul 20, 2026 | $14.555 | $14.75 | $13.11 | $13.34 | 12.07M |
| Jul 17, 2026 | $15.995 | $16.39 | $15.18 | $15.39 | 6.62M |
The latest Smart Investors Daily articles mentioning PSNL.
PSNL research
Company profile and research snapshot.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 20, 2026 | Needham | Hold | — |
| Jul 20, 2026 | BTIG | Buy | — |
| Jul 20, 2026 | Lake Street | Hold | — |
| Jul 17, 2026 | Needham | Buy | — |
| Jul 9, 2026 | Morgan Stanley | Equal-Weight | — |
No generated briefing is available yet.
Benzinga · Aug 4, 2026
Personalis (NASDAQ:PSNL) reported quarterly losses of $(0.30) per share which missed the analyst consensus estimate of $(0.27) by 15.38 percent. This is a 30.43 percent decrease over losses of $(0.23) per share from the
Benzinga · Jul 25, 2026
Benzinga examined the prospects for many investors’ favorite stocks over the last week — here’s a look at some of our top stories.
SeekingAlpha · Jul 21, 2026
Personalis, Inc. (PSNL) M&A Call July 20, 2026 9:00 AM EDTCompany ParticipantsElizabeth Krutoholow - Vice President of Investor Relations &...
SeekingAlpha · Jul 20, 2026
2026-07-20. The following slide deck was published by Personalis, Inc.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning PSNL.
